DNA vaccine for cancer immunotherapy

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3153-3164

  Yang, Benjamin ^a   Jeang, Jessica ^a   Yang, Andrew ^a   Wu, T C ^a,b   Hung, Chien Fu ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cellular immune response; DNA vaccines; Humoral immune response; Immune tolerance; Tumor antigens; Vaccine delivery

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN GP 100; MAMMAGLOBIN A; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN E6; PROTEIN E7; CANCER VACCINE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DNA VECTOR; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPOIESIS; MELANOMA; NONHUMAN; PLASMID; PROSTATE CANCER; RISK BENEFIT ANALYSIS; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ANIMAL; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PROCEDURES; TUMOR ESCAPE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; TUMOR ESCAPE; VACCINATION; VACCINES, DNA;

EID: 84921903497     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.980686     Document Type: Article

References (105)

1. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 1953; 276:1-103; PMID:13039964
2. Wolff JA, Malone RW, Williams P, ChongW, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID: 1690918; http://dx.doi.org/10.1126/science.1690918
3. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 1994; 91:9519-23.
4. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; PMID: 8456302; http://dx.doi.org/10.1126/science.8456302
5. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993; 90:4156-60.
6. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999; 170:85-100; PMID:10566144; http://dx.doi.org/10.1111/j.1600-065X.1999.tb01331.x
7. Smith HA. Regulation and review of DNA vaccine products. Dev Biol 2000; 104:57-62; PMID: 11713825
8. Rinaldi M, Signori E, Rosati P, Cannelli G, Parrella P, Iannace E, Monego G, Ciafre SA, Farace MG, Iurescia S, et al. Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety. Vaccine 2006; 24:4586-91; PMID:16154671; http://dx.doi.org/10.1016/j.vaccine.2005.08.030
9. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178:92-100; PMID:9652427; http://dx.doi.org/10.1086/515613
10. Gallegos AM, Bevan MJ. Central tolerance: good but imperfect. Immunol Rev 2006; 209:290-6; PMID:16448550; http://dx.doi.org/10.1111/j.0105-2896.2006.00348.x
11. Kreuwel HT, Sherman LA. The T-cell repertoire available for recognition of self-antigens. Curr Opin Immunol 2001; 13:639-43; PMID:11677083; http://dx.doi.org/10.1016/S0952-7915(01)00272-2
12. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
13. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207; PMID:15309328; http://dx.doi.org/10.1007/s00262-004-0560-6
14. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7; PMID:1840703; http://dx.doi.org/10.1126/science.1840703
15. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100:2014-21; PMID:19719775; http://dx.doi.org/10.1111/j.1349-7006.2009.01303.x
16. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188:51-64; PMID:12445281; http://dx.doi.org/10.1034/j.1600-065X.2002.18806.x
17. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187:265-70; PMID:9432985; http://dx.doi.org/10.1084/jem.187.2.265
18. Garcia Leme J, Morato M, Souza MZ. Anti-inflammatory action of glucagon in rats. Br J Pharmacol 1975; 55:65-8; PMID:1182350; http://dx.doi.org/10.1111/j.1476-5381.1975.tb07611.x
19. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 2012;109:5797-802.
20. de Carvalho F, Vettore AL, Colleoni GW. Cancer/ Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol 2012; 2012:257695; PMID:22481966
21. Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kroger N, Atanackovic D. Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer J 2014; 4:e212; PMID:24813080; http://dx.doi.org/10.1038/bcj.2014.31
22. Goodison S, Urquidi V. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management. Biomark Med 2012; 6:629-32; PMID:23075240; http://dx.doi.org/10.2217/bmm.12.65
23. Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2014; 2:371-9; PMID:24764584; http://dx.doi.org/10.1158/2326-6066.CIR-13-0088
24. Lowe DB, Shearer MH, Jumper CA, Kennedy RC. Towards progress on DNA vaccines for cancer. Cell Mol Life Sci 2007; 64:2391-403; PMID:17565444; http://dx.doi.org/10.1007/s00018-007-7165-0
25. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16:413-28; PMID:9831867; http://dx.doi.org/10.1002/stem.160413
26. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23-34; PMID: 21048000; http://dx.doi.org/10.1128/CVI.00286-10
27. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-9; PMID:8113668; http://dx.doi.org/10.1084/jem.179.3.1005
28. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184:2207-16; PMID:8976176; http://dx.doi.org/10.1084/jem.184.6.2207
29. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52; PMID:7516411; http://dx.doi.org/10.1084/jem.180.1.347
30. Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 1998; 114:166-72; PMID:9822272; http://dx.doi.org/10.1046/j.1365-2249.1998.00678.x
31. Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, Mohanakumar T. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer 2002; 102:499-506; PMID:12432553; http://dx.doi.org/10.1002/ijc.10736
32. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002; 20:2197-207; PMID:11956282; http://dx.doi.org/10.1200/JCO.2002.08.017
33. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007; 178:1975-9; PMID:17277099; http://dx.doi.org/10.4049/jimmunol.178.4.1975
34. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 1995; 92:7976-80.
35. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 1996; 183:1173-83; PMID: 8642259; http://dx.doi.org/10.1084/jem.183.3.1173
36. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996; 183:1131-40; PMID:8642255; http://dx.doi.org/10.1084/jem.183.3.1131
37. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL, Jr., Boon T, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183:527-34; PMID:8627164; http://dx.doi.org/10.1084/jem.183.2.527
38. Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, Van den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304:587-90; PMID:15001714; http://dx.doi.org/10.1126/science.1095522
39. Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 1983; 304:165-7; PMID:6602947; http://dx.doi.org/10.1038/304165a0
40. Fox EJ, Salk JJ, Loeb LA. Cancer genome sequencing - an interim analysis. Cancer Res 2009; 69:4948-50; PMID:19509220; http://dx.doi.org/10.1158/0008-5472.CAN-09-1231
41. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009; 9:675-81; PMID:19701243; http://dx.doi.org/100.1038/nrc2717
42. Damania B. DNA tumor viruses and human cancer. Trends Microbiol 2007; 15:38-44; PMID:17113775; http://dx.doi.org/10.1016/j.tim.2006.11.002
43. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6:753-63; PMID:16990853; http://dx.doi.org/10.1038/nrc1973
44. Webster RG, Robinson HL. DNA vaccines: a review of developments. BioDrugs 1997; 8:273-92; PMID:18020519
45. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20; PMID:18219306; http://dx.doi.org/10.1038/nrc2326
46. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006; 25:135-54; PMID:16818369; http://dx.doi.org/10.1080/08830180600743057
47. Ulmer JB, Otten GR. Priming of CTL responses by DNA vaccines: direct transfection of antigen presenting cells versus cross-priming. Dev Biol 2000; 104:9-14; PMID:11713829
48. Hoebe K, Jiang Z, Tabeta K, Du X, Georgel P, Crozat K, Beutler B. Genetic analysis of innate immunity. Adv Immunol 2006; 91:175-226; PMID:16938541; http://dx.doi.org/10.1016/S0065-2776(06)91005-0
49. Kouji Kobiyama, Nao Jounai, Taiki Aoshi, Miyuki Tozuka, Fumihiko Takeshita, Cevayir Coban, and Ken J. Ishii. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines 2013; 1:278-92.
50. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008; 451:725-9; PMID:18256672; http://dx.doi.org/10.1038/nature06537
51. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461:788-92; PMID:19776740; http://dx.doi.org/10.1038/nature08476
52. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40:86-97; PMID:16997717; http://dx.doi.org/10.1016/j.ymeth.2006.05.022
53. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21:4036-42; PMID:12922140; http://dx.doi.org/10.1016/S0264-410X(03)00275-5
54. Lauterbach H, Gruber A, Ried C, Cheminay C, Brocker T. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol 2006; 176:4600-7; PMID:16585550; http://dx.doi.org/10.4049/jimmunol.176.8.4600
55. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188:1075-82; PMID:9743526; http://dx.doi.org/10.1084/jem.188.6.1075
56. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189:169-78; PMID:9874573; http://dx.doi.org/10.1084/jem.189.1.169
57. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3:362-71; PMID:9234241
58. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165:2850-8; PMID:10946318; http://dx.doi.org/10.4049/jimmunol.165.5.2850
59. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997; 186:1481-6; PMID:9348305; http://dx.doi.org/10.1084/jem.186.9.1481
60. Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol 1998; 160:5707-18; PMID:9637479
61. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012; 12:479-91; PMID:22728526; http://dx.doi.org/10.1038/nri3247
62. Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 2007; 25(Suppl 2):B24-34; PMID:17698262; http://dx.doi.org/10.1016/j.vaccine.2007.05.030
63. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010:174378; PMID: 20368780; http://dx.doi.org/10.1155/2010/174378
64. Ercole CJ, Oliveira Filho EK. Microsurgical vasovasostomy under local anesthesia: an outpatient setting. Semin Urol 1992; 10:180-3; PMID:1523372
65. Zhu D, Stevenson FK. DNA gene fusion vaccines against cancer. Curr Opin Mol Ther 2002; 4:41-8; PMID:11883694
66. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immunity 2009; 9:5; PMID: 19496531
67. Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine 2011; 29:6817-22; PMID:21195077; http://dx.doi.org/10.1016/j.vaccine.2010.12.063
68. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7; PMID:19118066; http://dx.doi.org/10.1158/1078-0432.CCR-08-1725
69. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90:11478-82
70. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16:867-70; PMID:9743122; http://dx.doi.org/10.1038/nbt0998-867
71. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6:508-14; PMID:10476210; http://dx.doi.org/10.1038/sj.gt.3300847
72. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011; 23:421-9; PMID:21530212; http://dx.doi.org/10.1016/j.coi.2011.03.008
73. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Hoglund U, Blomberg P, Fons M, Mathiesen I, Sallberg M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007; 179:4741-53; PMID:17878373; http://dx.doi.org/10.4049/jimmunol.179.7.4741
74. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008; 82:5643-9; PMID:18353952; http://dx.doi.org/10.1128/JVI.02564-07
75. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164:4635-40; PMID:10779767; http://dx.doi.org/10.4049/jimmunol.164.9.4635
76. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, Babiuk LA. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20:3399-408; PMID:12213410; http://dx.doi.org/10.1016/S0264-410X(02)00269-4
77. Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, Huygen K, Mathiesen I. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002; 20:3370-8; PMID:12213407; http://dx.doi.org/10.1016/S0264-410X(02)00289-X
78. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20:1269-78; PMID: 19619001; http://dx.doi.org/10.1089/hum.2009.067
79. Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Translat Med 2013; 11:62; PMID:23497415; http://dx.doi.org/10.1186/1479-5876-11-62
80. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003; 9:33-9; PMID:12496961; http://dx.doi.org/10.1038/nm813
81. Kang TH, Mao CP, La V, Chen A, Hung CF, Wu TC. Innovative DNA vaccine to break immune tolerance against tumor self-antigen. Hum Gene Ther 2013; 24:181-8; PMID:23268564; http://dx.doi.org/10.1089/hum.2012.141
82. Soong RS, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PloS One 2013; 8:e56912; PMID:23457640; http://dx.doi.org/10.1371/journal.pone.0056912
83. Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY, Weiner DB. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res 2013; 1:179-89; PMID:24777680; http://dx.doi.org/10.1158/2326-6066.CIR-13-0001
84. Aurisicchio L, Peruzzi D, Koo G, Wei WZ, La Monica N, Ciliberto G. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Human Gene Therapy 2014; 25:121-31; PMID:24195644; http://dx.doi.org/10.1089/hum.2013.103
85. Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, et al. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol Immunother 2008; 57:1635-45; PMID:18386000; http://dx.doi.org/10.1007/s00262-008-0497-2
86. Joseph-Pietras D, Gao Y, Zojer N, Ait-Tahar K, Banham AH, Pulford K, Rice J, Savelyeva N, Sahota SS. DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma. Leukemia 2010; 24:1951-9; PMID:20861911; http://dx.doi.org/10.1038/leu.2010.196
87. Campos-Perez J, Rice J, Escors D, Collins M, Paterson A, Savelyeva N, Stevenson FK. DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. Int J Cancer 2013; 133:1400-7; PMID:23494538; http://dx.doi.org/10.1002/ijc.28156
88. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004; 22:1700-8; PMID: 15068853; http://dx.doi.org/10.1016/j.vaccine.2003.10.048
89. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006; 66:4904-12; PMID:16651447; http://dx.doi.org/10.1158/0008-5472.CAN-05-2813
90. Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PloS One 2014; 9:e93162; PMID:24664420; http://dx.doi.org/10.1371/journal.pone.0093162
91. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9:1284-90; PMID: 12684396
92. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract 2007; 22:55-60; PMID:17591290; http://dx.doi.org/10.1053/j.ctsap.2007.03.004
93. USDA licenses DNA vaccine for treatment of melanoma in dogs. J Am Vet Med Assoc 2010; 236:495; PMID:20187810; http://dx.doi.org/10.2460/javma.236.5.488
94. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, 2nd, Harper LB, Beare CM, Bagdon WJ, Nichols WW. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000; 43:258-72; PMID:11251381; http://dx.doi.org/10.1159/000053993
95. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, et al. Phase 1 trial of intranodal injection of a Melan-A/ MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008; 31:215-23; PMID: 18481391; http://dx.doi.org/10.1097/CJI.0b013e3181611420
96. Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res 2010; 16:4057-65; PMID:20647477; http://dx.doi.org/10.1158/1078-0432.CCR-10-1093
97. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Translat Med 2010; 8:53; PMID:20529245; http://dx.doi.org/10.1186/1479-5876-8-53
98. Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C, et al. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. Clin Cancer Res 2014; 20:2910-21; PMID:24668647; http://dx.doi.org/10.1158/1078-0432.CCR-13-2663
99. Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat 2013; 138:109-18; PMID:22678162; http://dx.doi.org/10.1007/s10549-012-2110-9
100. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:4047-54; PMID:19636017; http://dx.doi.org/10.1200/JCO.2008.19.9968
101. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639-47; PMID:20551832; http://dx.doi.org/10.1097/CJI.0b013e3181dda23e
102. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012; 61:2161-70; PMID:22729556; http://dx.doi.org/10.1007/s00262-012-1270-0
103. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra38; PMID:23052295; http://dx.doi.org/10.1126/scitranslmed.3004414
104. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, Desmarais C, Boyer JD, Tycko B, Robins HS, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 2014; 6:221ra13; PMID:24477000; http://dx.doi.org/10.1126/scitranslmed.3007323
105. Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C, et al. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. Clin Cancer Res 2014; PMID:24668647; http://dx.doi.org/10.1158/1078-0432.CCR-13-2663